2024-2025 COVID-19 Vaccine and Major Adverse Cardiovascular Events Among US Veterans

Is receipt of the 2024-2025 COVID-19 vaccine associated with a lower risk of COVID-19–associated major adverse cardiovascular event (MACE)?This cohort study including 1 039 659 participants from the US Department of Veterans Affairs found that the 2024-2025 COVID-19 vaccine was associated with a lower risk of COVID-19–associated MACE, with more prominent risk reductions among those 75 years or older and those with comorbidities. Secondary analyses of all-cause MACE showed substantially larger absolute risk reductions.Receipt of the 2024-2025 COVID-19 vaccine was associated with reduced COVID-19–associated cardiovascular risk; evidence of vaccine effectiveness against the broader outcome (all-cause MACE) likely reflects the hidden burden of undetected SARS-CoV-2 and associated complications that are amenable to reduction by COVID-19 vaccination.

Corresponding Author: Ziyad Al-Aly, MD, VA St Louis Health Care System, 915 N Grand Blvd, 151-JC, St Louis, MO 63106 (ziyad.alaly@va.gov).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.